The Truncated Isoform of Somatostatin Receptor5 (sst5TMD4) Is Associated with Poorly Differentiated Thyroid Cancer
Puig Domingo, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Luque, Raúl M. (Instituto Maimónides de Investigación Biomédica de Córdoba)
Reverter, Jordi L. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
López-Sánchez, Laura M. (Instituto Maimónides de Investigación Biomédica de Córdoba)
Gahete, Manuel D. (Instituto Maimónides de Investigación Biomédica de Córdoba)
Culler, Michael D. (IPSEN, Milford, Massachusetts, United States of America)
Díaz-Soto, Gonzalo (Hospital Clínico Universitario de Valladolid)
Lomeña, Francisco (Hospital Clínic i Provincial de Barcelona)
Squarcia, Mattia (Hospital Clínic i Provincial de Barcelona)
Mate Sanz, Jose Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Mora, Mireia (Hospital Clínic i Provincial de Barcelona)
Fernández-Cruz, Laureano (Hospital Clínic i Provincial de Barcelona)
Vidal, Oscar (Hospital Clínic i Provincial de Barcelona)
Alastrue Vidal, Antonio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Balibrea Del Castillo, José María (Hospital Universitari Vall d'Hebron)
Halperin, Irene (Hospital Clínic i Provincial de Barcelona)
Mauricio Puente, Dídac (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Castaño, Justo P. (Instituto Maimónides de Investigación Biomédica de Córdoba)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2014
Resum:	Somatostatin receptors (ssts) are expressed in thyroid cancer cells, but their biological significance is not well understood. The aim of this study was to assess ssts in well differentiated (WDTC) and poorly differentiated thyroid cancer (PDTC) by means of imaging and molecular tools and its relationship with the efficacy of somatostatin analog treatment. Thirty-nine cases of thyroid carcinoma were evaluated (20 PDTC and 19 WDTC). Depreotide scintigraphy and mRNA levels of sst-subtypes, including the truncated variant sst5TMD4, were carried out. Depreotide scans were positive in the recurrent tumor in the neck in 6 of 11 (54%) PDTC, and in those with lung metastases in 5/11 cases (45. 4%); sst5TMD4 was present in 18/20 (90%) of PDTC, being the most densely expressed sst-subtype, with a 20-fold increase in relation to sst2. In WDTC, sst2 was the most represented, while sst5TMD4 was not found; sst2 was significantly increased in PDTC in comparison to WDTC. Five depreotide positive PDTC received octreotide for 3-6 months in a pilot study with no changes in the size of the lesions in 3 of them, and a significant increase in the pulmonary and cervical lesions in the other 2. All PDTC patients treated with octreotide showed high expression of sst5TMD4. ROC curve analysis demonstrated that only sst5TMD4 discriminates between PDTC and WDTC. We conclude that sst5TMD4 is overexpressed in PDTC and may be involved in the lack of response to somatostatin analogue treatment.
Ajuts:	Ministerio de Ciencia e Innovación BFU2010-19300 Ministerio de Ciencia e Innovación CD11/00276 Ministerio de Ciencia e Innovación JCI-2009-05675
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	PloS one, Vol. 9 (january 2014) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0085527
PMID: 24465589

7 p, 894.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Neurociències (INc)
Articles > Articles de recerca
Articles > Articles publicats